Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1868

1.

"Variant specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay". Is dPCR the key?

Bernardi S, Bonifacio M, Iurlo A, Zanaglio C, Tiribelli M, Binotto G, Abruzzese E, Russo D.

Eur J Haematol. 2019 Jun 24. doi: 10.1111/ejh.13282. [Epub ahead of print]

PMID:
31233644
2.

Signaling pathways involved in chronic myeloid leukemia pathogenesis: The importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells.

Moradi F, Babashah S, Sadeghizadeh M, Jalili A, Hajifathali A, Roshandel H.

Iran J Basic Med Sci. 2019 Jun;22(6):581-589. doi: 10.22038/ijbms.2019.31879.7666. Review.

PMID:
31231484
3.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP; International CML Foundation Genomics Alliance.

Leukemia. 2019 Jun 17. doi: 10.1038/s41375-019-0512-y. [Epub ahead of print] Review.

PMID:
31209280
4.

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.

Shih YT, Cortes JE, Kantarjian HM.

Lancet Haematol. 2019 Jun 14. pii: S2352-3026(19)30087-0. doi: 10.1016/S2352-3026(19)30087-0. [Epub ahead of print]

PMID:
31208943
5.
6.

[Clinical Study of SCIN Expression and Dromoter Methylation in Patients with Chronic Myeloid Leukemia].

Zhang ZH, Lian XY, Li XX, He PF, Lin J, Qian J.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Jun;27(3):646-651. doi: 10.19746/j.cnki.issn.1009-2137.2019.03.003. Chinese.

PMID:
31204912
7.

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.

Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L, O'Brien SG, Read L, Foroni L, Copland M.

Lancet Haematol. 2019 Jun 11. pii: S2352-3026(19)30094-8. doi: 10.1016/S2352-3026(19)30094-8. [Epub ahead of print]

PMID:
31201085
8.

Large amplicon droplet digital PCR for DNA-based monitoring of pediatric chronic myeloid leukaemia.

Krumbholz M, Goerlitz K, Albert C, Lawlor J, Suttorp M, Metzler M.

J Cell Mol Med. 2019 Jun 14. doi: 10.1111/jcmm.14321. [Epub ahead of print]

9.

Atypical chronic myeloid leukemia BCR-ABL 1 negative: A case report and literature review.

Belkhair J, Raissi A, Elyahyaoui H, Ameur MA, Chakour M.

Leuk Res Rep. 2019 May 25;12:100172. doi: 10.1016/j.lrr.2019.100172. eCollection 2019.

10.

A Novel Case of ABL2 Chromosomal Rearrangement in High-Risk B-Cell Acute Lymphoblastic Leukemia.

Rohil Y, Shetty D, Narula G, Banavali SD.

J Assoc Genet Technol. 2019;45(2):73-76.

PMID:
31189154
11.

Mutations Associated with Imatinib Mesylate Resistance - Review.

Linev AJ, Ivanov HJ, Zhelyazkov IG, Ivanova H, Goranova-Marinova VS, Stoyanova VK.

Folia Med (Plovdiv). 2018 Dec 1;60(4):617-623. doi: 10.2478/folmed-2018-0030. Review.

PMID:
31188765
12.

Dasatinib-induced nephrotic syndrome: a case of phenoconversion.

Mandac Rogulj I, Matišić V, Arsov B, Boban L, Juginović A, Molnar V, Primorac D.

Croat Med J. 2019 Jun 13;60(3):250-254.

13.

Conventional and molecular cytogenetic studies to characterize 32 complex variant Philadelphia translocations in patients with chronic myeloid leukemia.

Costa D, Grau J, Espinet B, Arias A, Gómez C, López-Guerra M, Nomdedeu M, Cervantes F.

Oncol Lett. 2019 Jun;17(6):5705-5710. doi: 10.3892/ol.2019.10245. Epub 2019 Apr 12.

14.

Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1.

Xu D, Claudiani S, Naresh K, Mucklow S, Neelakantan P, Yebra E, Apperley JF, Khorashad J, Milojkovic D.

Leuk Lymphoma. 2019 Jun 11:1-2. doi: 10.1080/10428194.2019.1622101. [Epub ahead of print] No abstract available.

PMID:
31184233
15.

Philadelphia chromosome-positive acute lymphoblastic leukemia with an e14a3 BCR-ABL1 fusion: The role of molecular monitoring.

Crampe M, Langabeer SE, O'Brien D, Ryan E, Bacon CL.

Hematol Oncol Stem Cell Ther. 2019 May 28. pii: S1658-3876(19)30039-1. doi: 10.1016/j.hemonc.2019.04.001. [Epub ahead of print] No abstract available.

16.

Myeloproliferative neoplasms (MPNs) - Part 1: An overview of the diagnosis and treatment of the "classical" MPNs.

Fowlkes S, Murray C, Fulford A, De Gelder T, Siddiq N.

Can Oncol Nurs J. 2018 Oct 1;28(4):262-268. doi: 10.5737/23688076284262268. eCollection 2018 Fall.

17.

Myeloproliferative neoplasms (MPNs) - Part 2: A nursing guide to managing the symptom burden of MPNs.

Fowlkes S, Murray C, Fulford A, De Gelder T, Siddiq N.

Can Oncol Nurs J. 2018 Oct 1;28(4):276-281. doi: 10.5737/23688076284276281. eCollection 2018 Fall.

18.

Evidence for BCR/ABL1-positive T-cell acute lymphoblastic leukemia arising in an early lymphoid progenitor cell.

Ragg S, Zehentner BK, Loken MR, Croop JM.

Pediatr Blood Cancer. 2019 May 28:e27829. doi: 10.1002/pbc.27829. [Epub ahead of print]

PMID:
31136068
19.

Unique characteristics of leukocyte volume, conductivity and scatter in chronic myeloid leukemia.

Gaspar BL, Sharma P, Varma N, Sukhachev D, Bihana I, Naseem S, Malhotra P, Varma S.

Biomed J. 2019 Apr;42(2):93-98. doi: 10.1016/j.bj.2018.12.004. Epub 2019 May 6.

20.

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib.

Kok CH, Yeung DT, Lu L, Watkins DB, Leclercq TM, Dang P, Saunders VA, Reynolds J, White DL, Hughes TP.

Blood Adv. 2019 May 28;3(10):1610-1621. doi: 10.1182/bloodadvances.2019000195.

Supplemental Content

Loading ...
Support Center